Advertisement
Screener

Protalix BioTherapeutics, Inc. (PLX) Net Cash Provided by (Used in) Investing Activities, Continuing Operations

2.8 / 5 stars · 68/120 Roast Me

Protalix BioTherapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations

Protalix BioTherapeutics, Inc. (PLX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$1.12 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-06.

Discontinued › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-03-06

  • Protalix BioTherapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2015-12-31 was $4.00K.
  • Protalix BioTherapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2015-09-30 was -$169.00K.
  • Protalix BioTherapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2015-06-30 was -$248.00K.
  • Protalix BioTherapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2015-03-31 was -$99.00K.
  • Protalix BioTherapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$1.12M.
  • Protalix BioTherapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$967.00K.
  • Protalix BioTherapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$512.00K.
  • Protalix BioTherapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$1.00M.
Period endNet Cash Provided by (Used in) Investing Activities, Continuing Operations 3 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 6 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month
2017-12-31-$1.12M
10-K · filed 2018-03-06
2016-12-31-$967.00K
10-K · filed 2018-03-06
2015-12-31$4.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06
-$165.00K
derived: sum of 2 quarters · filed 2018-03-06
-$413.00K
derived: sum of 3 quarters · filed 2018-03-06
-$512.00K
10-K · filed 2018-03-06
2015-09-30-$169.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
-$417.00K
derived: sum of 2 quarters · filed 2015-11-09
-$516.00K
10-Q · filed 2015-11-09
-$685.00K
derived: sum of 4 quarters · filed 2017-03-16
2015-06-30-$248.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10
-$347.00K
10-Q · filed 2015-08-10
-$516.00K
derived: sum of 3 quarters · filed 2017-03-16
-$783.00K
derived: sum of 4 quarters · filed 2017-03-16
2015-03-31-$99.00K
10-Q · filed 2015-05-07
-$268.00K
derived: sum of 2 quarters · filed 2017-03-16
-$535.00K
derived: sum of 3 quarters · filed 2017-03-16
-$730.00K
derived: sum of 4 quarters · filed 2017-03-16
2014-12-31-$169.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
-$436.00K
derived: sum of 2 quarters · filed 2017-03-16
-$631.00K
derived: sum of 3 quarters · filed 2017-03-16
-$1.00M
10-K · filed 2017-03-16
2014-09-30-$267.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
-$462.00K
derived: sum of 2 quarters · filed 2015-11-09
-$832.00K
10-Q · filed 2015-11-09
-$1.10M
derived: sum of 4 quarters · filed 2016-03-08
2014-06-30-$195.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10
-$565.00K
10-Q · filed 2015-08-10
-$836.00K
derived: sum of 3 quarters · filed 2016-03-08
-$1.25M
derived: sum of 4 quarters · filed 2016-03-08
2014-03-31-$370.00K
10-Q · filed 2015-05-07
-$641.00K
derived: sum of 2 quarters · filed 2016-03-08
-$1.06M
derived: sum of 3 quarters · filed 2016-03-08
-$1.78M
derived: sum of 4 quarters · filed 2016-03-08
2013-12-31-$271.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08
-$690.00K
derived: sum of 2 quarters · filed 2016-03-08
-$1.41M
derived: sum of 3 quarters · filed 2016-03-08
-$2.10M
10-K · filed 2016-03-08
2013-09-30-$419.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10
-$1.14M
derived: sum of 2 quarters · filed 2014-11-10
-$1.83M
10-Q · filed 2014-11-10
2013-06-30-$723.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
-$1.41M
10-Q · filed 2014-08-07
2013-03-31-$689.00K
10-Q · filed 2014-05-08
2012-12-31-$2.29M
10-K · filed 2015-03-12
2011-12-31-$5.87M
10-K · filed 2014-03-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
Alector, Inc. (ALEC)United States$0.213B-1.90
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95